Phoenicis

Phoenicis start-up company is focused on the development of an innovative disease-modifying candidate targeting a key enzyme involved in inflammatory processes: the myeloperoxydase (MPO), already clinically validated in diverse severe conditions. The vision of Phoenicis is to develop its lead candidate in diverse relevant indications characterized by high unmet needs after the early success of its first program focused in vasculitis.